阿罗洛尔治疗慢性心衰的疗效及其对血浆脑钠肽的影响

Therapeutic effect of arotinolol on chronic heart failure and its influence on plasma BNP level

目的:研究盐酸阿罗洛尔治疗慢性心衰(CHF)的疗效及其对血浆脑钠尿肽(BNP)的影响。方法:选择我院收治的CHF患者116例,依据随机数字表法均分为常规治疗组和阿罗洛尔组(常规治疗基础上联合阿罗洛尔治疗)。连续治疗6个月。观察两组治疗前后左室收缩末期容积(LVESV)、左室舒张末期容积(LVEDV)、左室射血分数(LVEF)、心肌能量消耗(MEE);血清白介素8 (IL-8)、高敏C反应蛋白(hsCRP)等炎性因子水平;血浆BNP水平;Lee心衰积分及不良反应。结果:治疗后,与常规治疗组比较,阿罗洛尔组LVESV [(38.45±3.93)ml比(36.42±3.51)ml]、LVEDV [(49.23±4.89)ml比(47.43±4.37)ml]、MEE [(96.11±9.86)cal/min比(86.58±8.83)cal/min]明显减小,IL-8 [(32.18±3.17)ng/L比(28.92±2.79)ng/L]、hsCRP [(5.86±0.51)mg/L比(3.78±0.35)mg/L]、BNP [(275.75±27.64)ng/L比(196.75±20.04)ng/L]水平及Lee心衰积分[(4.77±0.73)分比(2.82±0.54)分]明显降低,LVEF [(45.69±4.76)%比(51.89±5.30)%]明显提高(P<0.05或<0.01)。阿罗洛尔组总有效率明显高于常规治疗组(94.83%比79.31%,P=0.027)。两组治疗期间均无明显不良反应。结论:阿罗洛尔可显著改善心力衰竭患者心功能,降低血浆脑钠肽及炎性因子水平,疗效显著,安全可靠。

Objective:To study therapeutic effect of arotinolol hydrochloride on chronic heart failure(CHF)and its influence on plasma levels of brain natriuretic peptide(BNP).Methods:A total of116CHF patients treated in our hospital were selected,randomly and equally divided into routine treatment group and arotinolol group(received arotinolol based on routine treatment),both groups were continuously treated for six months.Left ventricular end-systolic volume(LVESV),left ventricular end-diastolic volume(LVEDV),left ventricular ejection fraction(LVEF),myocardial energy expenditure(MEE),serum levels of interleukin(IL)-8and high sensitive C reactive protein(hsCRP),plasma BNP level,Lee heart failure score and incidence of adverse reactions were observed and compared between two groups before and after treatment.Results:Compared with routine treatment group after treatment,there were significant reductions in LVESV[(38.45±3.93)ml vs.(36.42±3.51)ml],LVEDV[(49.23±4.89)ml vs.(47.43±4.37)ml],MEE[(96.11±9.86)cal/min vs.(86.58±8.83)cal/min],levels of IL-8[(32.18±3.17)ng/L vs.(28.92±2.79)ng/L],hsCRP[(5.86±0.51)mg/L vs.(3.78±0.35)mg/L],BNP[(275.75±27.64)ng/L vs.(196.75±20.04)ng/L]and Lee heart failure score[(4.77±0.73)scores vs.(2.82±0.54)scores],and significant rise in LVEF[(45.69±4.76)%vs.(51.89±5.30)%]in arotinolol group,P<0.05or<0.01.Total effective rate of arotinolol group was significantly higher than that of routine treatment group(94.83%vs.79.31%,P=0.027).There were no obvious adverse reactions in two groups during treatment.Conclusion:Arotinolol can significantly improve heart function,reduce plasma BNP and inflammatory factor levels in CHF patients.The therapeutic effect is significant,and it's safe and reliable.